company background image
LBPH logo

Longboard Pharmaceuticals NasdaqGM:LBPH Stock Report

Last Price

US$21.60

Market Cap

US$755.6m

7D

8.2%

1Y

459.6%

Updated

28 Mar, 2024

Data

Company Financials +

Longboard Pharmaceuticals, Inc.

NasdaqGM:LBPH Stock Report

Market Cap: US$755.6m

LBPH Stock Overview

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases.

LBPH fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Longboard Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Longboard Pharmaceuticals
Historical stock prices
Current Share PriceUS$21.60
52 Week HighUS$28.15
52 Week LowUS$3.60
Beta1.29
1 Month Change-7.69%
3 Month Change258.21%
1 Year Change459.59%
3 Year Change34.66%
5 Year Changen/a
Change since IPO29.73%

Recent News & Updates

Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely

Mar 16

Recent updates

Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely

Mar 16

Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?

Oct 03
Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?

We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate

Dec 25
We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate

Companies Like Longboard Pharmaceuticals (NASDAQ:LBPH) Are In A Position To Invest In Growth

Sep 10
Companies Like Longboard Pharmaceuticals (NASDAQ:LBPH) Are In A Position To Invest In Growth

We're Hopeful That Longboard Pharmaceuticals (NASDAQ:LBPH) Will Use Its Cash Wisely

May 28
We're Hopeful That Longboard Pharmaceuticals (NASDAQ:LBPH) Will Use Its Cash Wisely

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans

Feb 11
Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not At All Concerned With Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Situation

Oct 27
Here's Why We're Not At All Concerned With Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Situation

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business

Jun 12
Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business

Longboard Pharmaceuticals EPS beats by $0.29

May 10

Shareholder Returns

LBPHUS PharmaceuticalsUS Market
7D8.2%2.2%0.2%
1Y459.6%25.5%28.1%

Return vs Industry: LBPH exceeded the US Pharmaceuticals industry which returned 25.8% over the past year.

Return vs Market: LBPH exceeded the US Market which returned 28.8% over the past year.

Price Volatility

Is LBPH's price volatile compared to industry and market?
LBPH volatility
LBPH Average Weekly Movement90.4%
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: LBPH's share price has been volatile over the past 3 months.

Volatility Over Time: LBPH's weekly volatility has increased from 46% to 90% over the past year.

About the Company

FoundedEmployeesCEOWebsite
202050Kevin Lindhttps://www.longboardpharma.com

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases.

Longboard Pharmaceuticals, Inc. Fundamentals Summary

How do Longboard Pharmaceuticals's earnings and revenue compare to its market cap?
LBPH fundamental statistics
Market capUS$755.64m
Earnings (TTM)-US$54.42m
Revenue (TTM)n/a

0.0x

P/S Ratio

-14.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LBPH income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$54.42m
Earnings-US$54.42m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.51
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did LBPH perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.